Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 7/20 | 0.48 |
| ▸ | HCRTR2 | O43614 | 7/20 | 0.48 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.48 |
| ▸ | TRPC6 | Q9Y210 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 8/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | GHSR | Q92847 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3542016 | 1.00 | HCRTR1 (0.48) | HCRTR1HCRTR2TRPC3TRPC6HTR2C | |
| SCHEMBL5665652 | 0.95 | HTR2C (0.48) | HCRTR1HCRTR2TRPC3TRPC6HTR2C | |
| SCHEMBL5661659 | 0.85 | SCD5 (0.52) | HCRTR1HCRTR2TRPC3TRPC6HTR2C | |
| SCHEMBL3539681 | 0.84 | HTR3E (0.55) | TRPC3TRPC6HTR2C | |
| SCHEMBL4975025 | 0.84 | HTR3E (0.55) | TRPC3TRPC6HTR2C | |
| SCHEMBL13548756 | 0.82 | HTR2C (0.47) | HCRTR1HCRTR2TRPC3TRPC6HTR2C | |
| SCHEMBL4971650 | 0.82 | HTR2C (0.47) | HCRTR1HCRTR2TRPC3TRPC6HTR2C | |
| SCHEMBL5661013 | 0.82 | HTR2C (0.63) | HTR2CNPC1RAB9AKMT2AHRH3 | |
| SCHEMBL5661113 | 0.82 | HTR2C (0.63) | HTR2CNPC1RAB9AKMT2AHRH3 | |
| SCHEMBL3536540 | 0.82 | CNR1 (0.45) | HCRTR1HCRTR2TRPC3TRPC6HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645773-B2 | Thiazoles as inhibitors of 11β-hydroxysteroid dehydrogenase | HOFFMANN-LA ROCHE INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20070167622-A1 | [2-(3-chloro-phenyl)-thiazol-4-yl]-(octahydro-quinolin-1-yl)-methanone; azocan-1-yl-[2-(2,3-dichloro-phenyl)-thiazol-4-yl]-methanone; type II diabetes mellitus and metabolic syndrome | GILLESPIE PAUL | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167622-A1 | [2-(3-chloro-phenyl)-thiazol-4-yl]-(octahydro-quinolin-1-yl)-methanone; azocan-1-yl-[2-(2,3-dichloro-phenyl)-thiazol-4-yl]-methanone; type II diabetes mellitus and metabolic syndrome | GOT2, PC, CYP11B2 | HCRTR1 2820/4885HCRTR2 1668/4885TRPC3 2595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.